NO311806B1 - Forbindelser tilhörende amidiniumfamilien, farmasöytiske preparater inneholdende disse samt anvendelse derav - Google Patents

Forbindelser tilhörende amidiniumfamilien, farmasöytiske preparater inneholdende disse samt anvendelse derav Download PDF

Info

Publication number: NO311806B1
Authority: NO; Norway
Prior art keywords: nucleic acid; pharmaceutical preparation; preparation according; transfection; cells
Prior art date: 1996-03-01

Application number

NO19983691A

Other languages

English (en)

Norwegian (no)

Other versions

NO983691D0 (no

NO983691L (no

Inventor

Jean-Marie Lehn

Pierre Lehn

Jean-Pierre Vigneron

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-01

Filing date

1998-08-12

Publication date

2002-01-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232562&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO311806(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-03-01 Priority claimed from FR9602604A external-priority patent/FR2745569B1/fr

1996-07-30 Priority claimed from FR9609557A external-priority patent/FR2751972B1/fr

1998-08-12 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

1998-08-12 Publication of NO983691D0 publication Critical patent/NO983691D0/no

1998-08-12 Publication of NO983691L publication Critical patent/NO983691L/no

2002-01-28 Publication of NO311806B1 publication Critical patent/NO311806B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 46
125000000909 amidinium group Chemical group 0.000 title abstract description 6
239000008194 pharmaceutical composition Substances 0.000 title 1
108090000623 proteins and genes Proteins 0.000 claims abstract description 55
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 33
230000001225 therapeutic effect Effects 0.000 claims abstract description 20
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
238000001890 transfection Methods 0.000 claims description 64
108020004414 DNA Proteins 0.000 claims description 49
108020004707 nucleic acids Proteins 0.000 claims description 32
102000039446 nucleic acids Human genes 0.000 claims description 32
150000007523 nucleic acids Chemical class 0.000 claims description 32
150000002632 lipids Chemical class 0.000 claims description 27
238000002360 preparation method Methods 0.000 claims description 23
239000000203 mixture Substances 0.000 claims description 19
239000000825 pharmaceutical preparation Substances 0.000 claims description 18
238000000338 in vitro Methods 0.000 claims description 14
230000007935 neutral effect Effects 0.000 claims description 14
238000000034 method Methods 0.000 claims description 12
235000012000 cholesterol Nutrition 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 5
229920002477 rna polymer Polymers 0.000 claims description 5
XWYZSQHTOLEYAO-UHFFFAOYSA-N 2-[4-(3-aminopropylamino)butyl-(diaminomethylideneamino)amino]guanidine Chemical group NCCCNCCCCN(N=C(N)N)N=C(N)N XWYZSQHTOLEYAO-UHFFFAOYSA-N 0.000 claims description 4
150000001841 cholesterols Chemical class 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
210000004400 mucous membrane Anatomy 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
238000001415 gene therapy Methods 0.000 abstract description 4
125000003282 alkyl amino group Chemical group 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 69
239000000243 solution Substances 0.000 description 33
239000002502 liposome Substances 0.000 description 32
108060001084 Luciferase Proteins 0.000 description 27
239000005089 Luciferase Substances 0.000 description 25
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 22
125000002091 cationic group Chemical group 0.000 description 20
MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 15
230000000694 effects Effects 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
238000001727 in vivo Methods 0.000 description 14
239000013612 plasmid Substances 0.000 description 14
239000000047 product Substances 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
238000012546 transfer Methods 0.000 description 12
-1 and so on Proteins 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 9
IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 9
230000001413 cellular effect Effects 0.000 description 9
239000002609 medium Substances 0.000 description 9
238000005160 1H NMR spectroscopy Methods 0.000 description 8
241000699670 Mus sp. Species 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
108010076504 Protein Sorting Signals Proteins 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000001514 detection method Methods 0.000 description 6
210000000981 epithelium Anatomy 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
238000005259 measurement Methods 0.000 description 6
210000000056 organ Anatomy 0.000 description 6
238000010186 staining Methods 0.000 description 6
238000003756 stirring Methods 0.000 description 6
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000012043 crude product Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
210000004907 gland Anatomy 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
239000000463 material Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
239000000725 suspension Substances 0.000 description 5
LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
239000007832 Na2SO4 Substances 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
241000700605 Viruses Species 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000010908 decantation Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000000921 elemental analysis Methods 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
239000007928 intraperitoneal injection Substances 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
239000012139 lysis buffer Substances 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 4
239000013598 vector Substances 0.000 description 4
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
102000005936 beta-Galactosidase Human genes 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
WDHJFGVUGNFBJK-UHFFFAOYSA-N bis[(2-methylpropan-2-yl)oxycarbonyl]carbamic acid Chemical compound CC(C)(C)OC(=O)N(C(O)=O)C(=O)OC(C)(C)C WDHJFGVUGNFBJK-UHFFFAOYSA-N 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
239000000693 micelle Substances 0.000 description 3
239000013642 negative control Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
230000007170 pathology Effects 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
229940063673 spermidine Drugs 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
108010071619 Apolipoproteins Proteins 0.000 description 2
102000007592 Apolipoproteins Human genes 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000002950 deficient Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000012637 gene transfection Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000009434 installation Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
239000011707 mineral Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
125000005342 perphosphate group Chemical group 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
102000005162 pleiotrophin Human genes 0.000 description 2
KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
238000000746 purification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
210000004878 submucosal gland Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
WBNTUGPRADFXAL-UHFFFAOYSA-N 1H-pyrazole-5-carboximidamide Chemical compound NC(=N)C=1C=CNN=1 WBNTUGPRADFXAL-UHFFFAOYSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
VDNMXEHWOCXKOZ-UHFFFAOYSA-N 2-[3-(4-aminobutylamino)propyl]guanidine Chemical compound NCCCCNCCCN=C(N)N VDNMXEHWOCXKOZ-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
ZXWQZGROTQMXME-WXUJBLQXSA-N 2-hydroxy-n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadec-4-en-2-yl]tetracosanamide Chemical class CCCCCCCCCCCCCCCCCCCCCCC(O)C(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZXWQZGROTQMXME-WXUJBLQXSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
102100022464 5'-nucleotidase Human genes 0.000 description 1
102100040214 Apolipoprotein(a) Human genes 0.000 description 1
101710115418 Apolipoprotein(a) Proteins 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010004942 Chylomicron Remnants Proteins 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
102000001039 Dystrophin Human genes 0.000 description 1
108010069091 Dystrophin Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
102000004038 Glia Maturation Factor Human genes 0.000 description 1
108090000495 Glia Maturation Factor Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
101000941289 Homo sapiens Hepatic triacylglycerol lipase Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
102000000853 LDL receptors Human genes 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000015336 Nerve Growth Factor Human genes 0.000 description 1
108090000742 Neurotrophin 3 Proteins 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000001107 Phosphatidate Phosphatase Human genes 0.000 description 1
108010069394 Phosphatidate Phosphatase Proteins 0.000 description 1
102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
102100032889 Sortilin Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
239000003914 blood derivative Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AQZNBAIWDZHJNK-UHFFFAOYSA-N ethanimidoyl cyanide Chemical compound CC(=N)C#N AQZNBAIWDZHJNK-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002598 fumaric acid Drugs 0.000 description 1
230000004927 fusion Effects 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
230000029226 lipidation Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
238000003670 luciferase enzyme activity assay Methods 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Substances CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000006362 methylene amino carbonyl group Chemical group [H]N(C([*:2])=O)C([H])([H])[*:1] 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
210000000633 nuclear envelope Anatomy 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
229940116315 oxalic acid Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
230000002000 scavenging effect Effects 0.000 description 1
230000009962 secretion pathway Effects 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
241000894007 species Species 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
JLEXUIVKURIPFI-UHFFFAOYSA-N tris phosphate Chemical compound OP(O)(O)=O.OCC(N)(CO)CO JLEXUIVKURIPFI-UHFFFAOYSA-N 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
General Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Dispersion Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Plant Pathology (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO19983691A 1996-03-01 1998-08-12 Forbindelser tilhörende amidiniumfamilien, farmasöytiske preparater inneholdende disse samt anvendelse derav NO311806B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9602604A FR2745569B1 (fr)	1996-03-01	1996-03-01	Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
FR9609557A FR2751972B1 (fr)	1996-07-30	1996-07-30	Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
PCT/FR1997/000364 WO1997031935A1 (fr)	1996-03-01	1997-02-28	Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications

Publications (3)

Publication Number	Publication Date
NO983691D0 NO983691D0 (no)	1998-08-12
NO983691L NO983691L (no)	1998-08-12
NO311806B1 true NO311806B1 (no)	2002-01-28

Family

ID=26232562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19983691A NO311806B1 (no)	1996-03-01	1998-08-12	Forbindelser tilhörende amidiniumfamilien, farmasöytiske preparater inneholdende disse samt anvendelse derav

Country Status (18)

Country	Link
US (2)	US6143729A (de)
EP (1)	EP0888379B1 (de)
JP (1)	JP4271260B2 (de)
KR (1)	KR19990087372A (de)
AT (1)	ATE198599T1 (de)
AU (1)	AU723998B2 (de)
BR (1)	BRPI9707889B8 (de)
CZ (1)	CZ295225B6 (de)
DE (1)	DE69703878T2 (de)
DK (1)	DK0888379T3 (de)
ES (1)	ES2154453T3 (de)
GR (1)	GR3035205T3 (de)
HU (1)	HU228072B1 (de)
IL (1)	IL125926A (de)
NO (1)	NO311806B1 (de)
PT (1)	PT888379E (de)
SK (1)	SK283575B6 (de)
WO (1)	WO1997031935A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6884430B1 (en)	1997-02-10	2005-04-26	Aventis Pharma S.A.	Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
FR2763943B1 (fr) *	1997-05-28	1999-07-09	Rhone Poulenc Rorer Sa	Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
JP2002513543A (ja) *	1998-04-02	2002-05-14	アバンテイス・フアルマ・エス・アー	新規核酸移入剤とそれらを含む組成物及びそれらの使用
FR2777017B1 (fr) *	1998-04-02	2002-08-23	Rhone Poulenc Rorer Sa	Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
DE10109898A1 (de) *	2001-02-21	2002-09-05	Novosom Gmbh	Lipide mit veränderlicher Ladung
FR2824557B1 (fr) *	2001-05-14	2003-08-29	Aventis Pharma Sa	Derives lipidiques de polythiouree
AU2002257904B2 (en) *	2001-05-14	2007-12-06	Gencell S.A.	Polythiourea lipid derivatives
FR2829136B1 (fr) *	2001-08-29	2006-11-17	Aventis Pharma Sa	Derives lipidiques d'aminoglycosides
AU2003205545A1 (en)	2002-01-17	2003-07-30	York Refrigeration Aps	Submerged evaporator with integrated heat exchanger
WO2006118283A1 (ja) *	2005-04-28	2006-11-09	Nippon Soda Co., Ltd.	新規なグアニジン化合物、製造方法及びそれらを含有する殺菌性組成物
CA2665403C (en) *	2006-10-04	2015-06-23	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof
EP2350296A4 (de) *	2008-11-17	2013-04-03	Enzon Pharmaceuticals Inc	Verzweigte kationische lipide für system zur zuführung von nukleinsäuren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5283185A (en) *	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
EP0730405A4 (de) *	1993-11-24	1997-02-19	Megabios Corp	Amphiphile guanidin-derivate
US5777153A (en) *	1994-07-08	1998-07-07	Gilead Sciences, Inc.	Cationic lipids
US6071890A (en) *	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5811406A (en) *	1995-06-07	1998-09-22	Regents Of The University Of California	Dry powder formulations of polynucleotide complexes

1997
- 1997-02-28 DE DE69703878T patent/DE69703878T2/de not_active Expired - Lifetime
- 1997-02-28 HU HU9902465A patent/HU228072B1/hu unknown
- 1997-02-28 SK SK1182-98A patent/SK283575B6/sk not_active IP Right Cessation
- 1997-02-28 PT PT97907154T patent/PT888379E/pt unknown
- 1997-02-28 DK DK97907154T patent/DK0888379T3/da active
- 1997-02-28 US US09/125,825 patent/US6143729A/en not_active Expired - Lifetime
- 1997-02-28 KR KR1019980706784A patent/KR19990087372A/ko active Granted
- 1997-02-28 WO PCT/FR1997/000364 patent/WO1997031935A1/fr not_active Ceased
- 1997-02-28 ES ES97907154T patent/ES2154453T3/es not_active Expired - Lifetime
- 1997-02-28 CZ CZ19982772A patent/CZ295225B6/cs not_active IP Right Cessation
- 1997-02-28 AT AT97907154T patent/ATE198599T1/de active
- 1997-02-28 JP JP53067797A patent/JP4271260B2/ja not_active Expired - Lifetime
- 1997-02-28 EP EP97907154A patent/EP0888379B1/de not_active Expired - Lifetime
- 1997-02-28 IL IL12592697A patent/IL125926A/en not_active IP Right Cessation
- 1997-02-28 BR BRPI9707889A patent/BRPI9707889B8/pt not_active IP Right Cessation
- 1997-02-28 AU AU19304/97A patent/AU723998B2/en not_active Expired
1998
- 1998-08-12 NO NO19983691A patent/NO311806B1/no not_active IP Right Cessation
2000
- 2000-11-06 US US09/706,619 patent/US6316422B1/en not_active Expired - Lifetime
2001
- 2001-01-11 GR GR20000402653T patent/GR3035205T3/el unknown

Also Published As

Publication number	Publication date
IL125926A (en)	2004-09-27
BR9707889B1 (pt)	2010-03-23
DE69703878T2 (de)	2001-04-26
DK0888379T3 (da)	2001-01-29
AU1930497A (en)	1997-09-16
KR19990087372A (ko)	1999-12-27
PT888379E (pt)	2001-05-31
JP2000506136A (ja)	2000-05-23
GR3035205T3 (en)	2001-04-30
US6316422B1 (en)	2001-11-13
DE69703878D1 (de)	2001-02-15
NO983691D0 (no)	1998-08-12
EP0888379B1 (de)	2001-01-10
JP4271260B2 (ja)	2009-06-03
EP0888379A1 (de)	1999-01-07
BRPI9707889B8 (pt)	2016-11-08
HU228072B1 (en)	2012-09-28
BR9707889A (pt)	2000-01-04
AU723998B2 (en)	2000-09-07
SK118298A3 (en)	1999-02-11
NO983691L (no)	1998-08-12
HUP9902465A1 (hu)	1999-12-28
KR100452062B1 (de)	2005-04-08
SK283575B6 (sk)	2003-09-11
ES2154453T3 (es)	2001-04-01
IL125926A0 (en)	1999-04-11
CZ277298A3 (cs)	1998-12-16
CZ295225B6 (cs)	2005-06-15
HUP9902465A3 (en)	2009-10-28
ATE198599T1 (de)	2001-01-15
WO1997031935A1 (fr)	1997-09-04
US6143729A (en)	2000-11-07

Legal Events

Date	Code	Title	Description
2017-03-13	MK1K	Patent expired

Publication	Publication Date	Title
US5935936A (en)	1999-08-10	Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US5948767A (en)	1999-09-07	Cationic amphiphile/DNA complexes
US5840710A (en)	1998-11-24	Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5925628A (en)	1999-07-20	Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5650096A (en)	1997-07-22	Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6071890A (en)	2000-06-06	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
AU731503B2 (en)	2001-03-29	Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US6383814B1 (en)	2002-05-07	Cationic amphiphiles for intracellular delivery of therapeutic molecules
WO1998002190A9 (en)	1998-12-17	Cationic amphiphile/dna complexes
US5948925A (en)	1999-09-07	Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
AU723998B2 (en)	2000-09-07	Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
US5747471A (en)	1998-05-05	Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US5942634A (en)	1999-08-24	Cationic amphiphiles for cell transfections
US5910487A (en)	1999-06-08	Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
WO1998045317A1 (en)	1998-10-15	Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
AU759197B2 (en)	2003-04-10	Transfecting compounds which are sensitive to reducing conditions, pharmaceutical compositions containing them and their applications
WO1999002190A1 (en)	1999-01-21	Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
CA2268945A1 (en)	1998-04-02	Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
WO1998050416A1 (en)	1998-11-12	Cationic amphiphiles containing multiple steroid lipophilic groups
CA2248186C (fr)	2006-09-19	Composes apparentes a la famille des amidiniums, compositions pharmaceutiques les contenant et leurs applications
MXPA98006892A (en)	1999-02-24	Compounds related to the amidinium family, pharmaceutical compositions containing them and their applications
AU734980B2 (en)	2001-06-28	Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
AU736143B2 (en)	2001-07-26	Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
AU3406100A (en)	2000-11-30	New agents for transferring nucleic acids, compositions containing them and their uses